Skip to content
drillr.ai
Sign up

MILE.CA

AstraZeneca PLC

Healthcare · Drug Manufacturers - General · GB

Also listed · AZN →AZN.CA →AZNVD →AZNVF →OJO.CA →
—
Ask drillr

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 9, 2026, 00:20 UTC

    On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.

    Source:

  • Sep 8, 2026, 13:15 UTC

    AstraZeneca announced on Tuesday that its cancer drug Imfinzi combined with Amgen's Imdelltra significantly improved overall survival in a late-stage trial for first-line extensive-stage small cell lung cancer.

    Source:

  • Sep 8, 2026, 11:45 UTC

    AstraZeneca announced that in the TITANIA study, Tozorakimab 300mg reduced the risk of moderate-to-severe exacerbations by 29% in the overall COPD patient population who are current or former smokers.

    Source:

  • Sep 8, 2026, 06:20 UTC

    China's Ministry of Commerce added 84 new key foreign-invested projects, including six landmark projects such as Fujian Benz Phase II and AstraZeneca's global strategic R&D center, with total investment of $19.46 billion.

    Source:

  • Sep 7, 2026, 14:20 UTC

    The US Food and Drug Administration granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for hormone receptor positive, HER2 negative metastatic breast cancer.

    Source:

  • Sep 2, 2026, 14:21 UTC

    AstraZeneca announced positive results from its SANOVO Phase III trial, showing that Tagrisso plus Orpathys improved progression-free survival in first-line EGFR-mutated non-small cell lung cancer.

    Source:

  • Sep 1, 2026, 06:05 UTC

    AstraZeneca completed its acquisition agreement for ZEGFROVY.

    Source:

  • Aug 31, 2026, 00:34 UTC

    Hutchison China MediTech announced positive topline results from the SANOVO China Phase III study of savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) in EGFR-mutant MET-overexpressing non-small cell lung cancer, showing statistically significant progression-free survival improvement.

    Source:

  • Aug 28, 2026, 09:23 UTC

    AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

    Source:

  • Aug 27, 2026, 06:00 UTC

    Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.

    Source:

  • Aug 26, 2026, 03:20 UTC

    Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.

    Source:

  • Aug 25, 2026, 06:52 UTC

    AstraZeneca PLC priced a €2.55 billion euro bond offering across four tranches, issued by its subsidiary AstraZeneca Finance LLC with a parent guarantee, for general corporate purposes.

    Source:

  • Aug 24, 2026, 12:30 UTC

    The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.

    Source:

  • Aug 24, 2026, 07:45 UTC

    The FTSE 100 index opened flat, easing 0.06% to 10,810, with AstraZeneca falling about 1% and FirstGroup dropping as much as 7% before recovering.

    Source:

  • Aug 21, 2026, 09:30 UTC

    AstraZeneca shares lost 0.86% to 11,984p on August 21, 2026.

    Source:

  • Aug 20, 2026, 10:04 UTC

    Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

    Source:

  • Aug 20, 2026, 08:55 UTC

    AstraZeneca's Ravulizumab received approval in China for a third indication, treating paroxysmal nocturnal hemoglobinuria (PNH), as shown on the NMPA website.

    Source:

  • Aug 18, 2026, 12:23 UTC

    On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

    Source:

  • Aug 17, 2026, 22:00 UTC

    The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.

    Source:

  • Aug 17, 2026, 13:22 UTC

    AstraZeneca discontinued a late-stage trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients lacking PD-L1, following a data monitoring committee recommendation.

    Source:

  • Aug 17, 2026, 06:28 UTC

    AstraZeneca announced on Monday that it is discontinuing a late-stage trial testing volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.

    Source:

  • Aug 17, 2026, 06:19 UTC

    AstraZeneca announced the official launch of Tezspire (tezepelumab) in China on August 17, 2026.

    Source:

  • Aug 10, 2026, 15:00 UTC

    A London-based drugmaker (AstraZeneca) announced plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years.

    Source:

  • Aug 7, 2026, 09:15 UTC

    Fresnillo surged 2.74% to 2,813p, Convatec Group advanced 2.73% to 233p, BAE Systems climbed 1.68% to 2,237p, London Stock Exchange Group gained 1.53% to 8,884p, Diageo rose 1.47% to 1,758p, and AstraZeneca added 1.38% to 12,014p.

    Source:

  • Aug 6, 2026, 10:15 UTC

    Tlwm acquired a new position in Astrazeneca Plc during the second quarter, purchasing 9,279 shares valued at approximately $1.76 million.

    Source:

  • Aug 5, 2026, 14:01 UTC

    AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.

    Source:

  • Aug 2, 2026, 19:36 UTC

    AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.

    Source:
Page 1Next →